Alpha Cognition Inc ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

NDAQ:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by XeniaTechieon Nov 17, 2021 12:44pm

162 Views

Post# 34136815

Watch the Alpha Cognition presentation from the Q4 Investors

Alpha Cognition CEO Michael McFadden presented this morning at the Q4 Investors Summit Group. This was a highly informative session that presented significant lab studies, data and commercialization strategies for their Alpha-1062 treatment which is essentially set to revolutionize the Alzheimer's treatment industry.

Tons of upside potential tapping into the $35B ALZ treatment market where 8/10 patients seek treatment and only 4.5/10 stay in treatments due to side-effects of current treatments, A-1062 is in trials and demonstrating strong improvement in side-effect profiles.

You can view the recording on-demand, here: https://us06web.zoom.us/webinar/register/WN_5oxO1tQORQKs2TZDYxM-yw

<< Previous

Bullboard Posts

Next >>

Crypto and blockchain stock ends year with a profit